Immunotherapy has been hailed as a revolutionary cancer treatment, but the reality is more complex. While some patients achieve dramatic, long-term remissions, others see little to no benefit. Understanding why immunotherapy works selectively is important for both patients and clinicians.
1. Tumor Mutations and Immunogenicity
Some cancers have a high mutation rate, resulting in more abnormal proteins (neoantigens) that the immune system recognizes. Tumors with low mutation rates may "fly under the radar," making them less visible to immune cells and thus less susceptible to immunotherapy.
2. Tumor Microenvironment (TME)
TME can actively suppress immune responses.
-
Tumors may recruit immunosuppressive cells (such as regulatory T cells) to prevent immune attacks.
-
Dense extracellular matrix or abnormal blood vessels can block immune cells from reaching tumor cells.
Simply put, the immune system can't always reach the battlefield.
3. Genetic Factors in the Patient
Patients' immune systems respond differently. Differences in immune cell composition, prior infections, and even gut microbiome health can all have an impact on immunotherapy effectiveness.
4. Therapy-Specific Factors
Various immunotherapies use different mechanisms:
-
Checkpoint inhibitors may fail if the tumor does not express the target proteins (such as PD-L1).
-
CAR-T therapies require the presence of specific tumor markers for effective targeting.
A poor match between therapy and tumor biology can limit outcomes.
Key Takeaway
Immunotherapy is not a one-size-fits-all treatment. Success is dependent on the complex interplay of tumor characteristics, patient genetics, and treatment type. Personalized approaches and predictive biomarkers will ensure that more patients benefit.